

Third Quarter 2024 Performance Summary

October 2024



TOTAL REVENUE

\$749 M +23% y/y¹



Tyvaso²

\$434M +33% y/y



Remodulin

\$128M -2% y/y



Orenitram

\$113M +23% y/y



Unituxin

\$61M +19% y/y



TTM OPERATING
CASH FLOW

\$1.1 billion



CASH, CASH EQUIVALENTS,
& MARKETABLE INVESTMENTS

\$4.6 billion

Quarterly Highlights



- Record total revenue
- 16th consecutive quarter of y/y revenue growth



- Most prescribed U.S. prostacyclin
- Highest revenue quarter ever



- Most prescribed parenteral prostacyclin in the U.S.
- Highest number of patients on therapy




orenitram[®]
treprostinil
EXTENDED-RELEASE TABLETS

- Eleventh sequential quarter of quarterly y/y revenue growth
- Highest revenue quarter ever



- Record total and U.S. revenue
- The most prescribed antibody therapy for high-risk neuroblastoma in the U.S.

Quarterly Revenue, millions USD



NASDAQ
UTHR

2023 Financials

PRODUCT REVENUE

~\$2.3 billion

REVENUE/EMPLOYEE

~\$2 million

FOUNDED

1996

HQ

Research Triangle Park, NC

Silver Spring, MD

EMPLOYEES

>1,100⁴

1. y/y = year over year. 2. Tyvaso DPI + nebulized Tyvaso. 3. CAGR = compound annual growth rate calculated from 3Q/19 to 3Q/24. 4. As of 12/31/2023

Pipeline

Development Engine Addressing Unmet Needs

Non-Registration Registration Approved

Tyvaso

TETON 1 - Idiopathic Pulmonary Fibrosis - U.S. and Canada	
TETON 2 - Idiopathic Pulmonary Fibrosis - ROW ¹	
TETON PPF - Progressive Pulmonary Fibrosis	

Ralinepag

ADVANCE OUTCOMES - PAH ²	
-------------------------------------	--

Organs and Organ Alternatives

EVLP ³ /CLES ⁴ - Lung Transplant	
miroliverELAP ⁵ - Acute Liver Failure	


Pre-clinical Xeno and Organ Alternative Programs

UKidney™	UHeart™	ULung™	miroliver®
UThymoKidney™	ULobe™	IVIVA Kidney	mirokidney®

Pipeline Spotlights

<p>TETON 2</p> <p>Fully Enrolled</p>	<p>TETON 1 COMPLETE ENROLLMENT TARGETED</p> <p>Year-End 2024</p>	<p>EVLP/CLES</p> <p>Premarket Approval Submitted</p>
--	--	--

Positioned for Multiple Waves of Growth⁶



This Fact Sheet contains forward-looking statements that are subject to risks and uncertainties, which are described in greater detail at ir.unither.com/disclaimer

1. ROW = rest of world outside the U.S. and Canada. 2. PAH = pulmonary arterial hypertension. 3. EVLP = ex-vivo lung perfusion. 4. CLES = centralized lung evaluation system. 5. ELAP = external liver assist product. 6. Illustrative purposes only

Learn More



United Therapeutics' Corporate Website



United Therapeutics' Investor Relations Website



United Therapeutics' LinkedIn



United Therapeutics' Corporate Responsibility Website

